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Case presentation
A 61-year-old Chinese man was admitted to Moffitt Hospital, Uni-
versity of California San Francisco, 3 years ago with a chief complaint
of swelling, a 17 lb weight gain, and progressive dyspnea on exertion for
the 2 weeks prior to admission.
The patient had noted pedal edema 7 months before admission.
Evaluation at that time disclosed a serum creatinine of 4 mg/dl; diuretics
were prescribed and he was seen by several nephrologists, the last of
whom treated him with oral prednisone, 60 mg daily; this medication
was quickly tapered after 3 weeks. When the swelling and dyspnea
persisted, the patient was referred to UCSF for evaluation.
A diagnosis of Graves' disease had been made in the past, and he was
treated with 1311 ablation; subsequently he developed hypothyroidism
and was given thyroid replacement medication daily. He also had a
history of anemia but no complaints of gastrointestinal dysfunction or
bleeding. He had no history of hepatitis, tuberculosis, hypertension,
diabetes, or heart disease. The patient smokes one-third of a pack of
cigarettes per day, drinks alcohol only occasionally, and has never used
intravenous drugs. He is a retired laundry worker who lives with his
wife. Medications at the time of admission included bumetanide, 1.5mg
daily; hydrochlorothiazide, 50 mg daily; prednisone, 10 mg daily;
levothyroxine, 0.075 mg daily; and iron sulfate tablets, intermittently.
Physical examination revealed a well-developed Asian man in no
obvious distress. His blood pressure was 110/78 mm Hg, heart rate, 104
beats/mm; respiratory rate, 20 beats/mm; and temperature, 37.5°C. The
jugular venous pressure was estimated at 8 cm. His tongue was swollen,
and the thyroid was not palpable. Both lungs were dull to percussion at
the bases and breath sounds were decreased. Cardiac examination
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showed a normal heart size and regular rhythm; heart sounds were
distant through a thickened chest wall, but no murmurs or gallops were
heard, The abdomen was nontender without evidence of hepatic or
splenic enlargement. The stool was guaiac positive. The extremities
showed no clubbing, but massive anasarca was present, with pitting
edema of all extremities as well as the abdominal and thoracic wall. The
penis and scrotum were edematous, and paraphimosis was evident,
Neurologic examination was normal except for a slowed relaxation
phase of the deep-tendon reflexes.
Laboratory values on admission were: hematocrit, 29.5; white blood
cell count, 16,700/mm3 with a left shift; and a platelet count of 212 x
103/mm'. The serum sodium concentration was 145 mEq/liter; potas-
sium, 4.3 mEq/liter; chloride, 121 mEq/liter; total CO2. 16 mmol/liter;
BUN, 65 mg/dl; and serum creatinine, 5.5 mgldl. The serum albumin
concentration was 0.6 g/dl; calcium, 6.9 mg/dl; phosphorus, 5.4 mg/dl;
and magnesium, 1.8 mg/dl. The erythrocyte sedimentation rate was 139
mm/hr, and the serum cholesterol was 554 mg/dl. Urinalysis disclosed a
specific gravity of 1.015, a pH of 6, and 4+ protein; microscopic
examination revealed 30—40 red blood cells/high-power field and many
hyaline and granular casts as well as oval fat bodies. A 24-hour
creatinine clearance test yielded a value of 8 mI/mm; the protein
excretion rate was 8.7 g/24 hr. A chest radiograph showed bilateral
pleural effusions and a mild increase in interstitial markings. Arterial
blood gas measurements obtained with the patient breathing room air
were: pH, 7.47; pCO2, 24 mm Hg; and p02, 105 mm Hg. An electro-
cardiogram showed normal sinus rhythm with diffuse low voltage.
Serum complement levels, antinuclear antibody, rheumatoid factor,
hepatitis B surface antigen, and antistreptococcal serologies all were
normal or negative. An abdominal ultrasound examination revealed
normal-sized kidneys without evidence of hydronephrosis; a renal MRI
scan showed patent renal veins without evidence of thrombosis.
The patient was believed to have idiopathic nephrotic syndrome. Oral
prednisone was tapered further and discontinued, and his diuretic
regimen was changed to intravenous furosemide, 80 mg every 8 hours,
and oral metolazone, 5 mg twice daily. Further diagnostic evaluation
included a rectal biopsy that was negative for amyloid. Thoracenteses
established that the pleural effusions were transudative in nature.
Gastroscopy revealed reflex esophagitis and several punctate gastric
ulcers. Thyroid function studies indicated that he was hypothyroid, and
the thyroxine dosage was increased; a cosyntropin stimulation test
revealed a normal cortisol response without evidence of adrenal insuf-
ficiency.
A percutaneous renal biopsy on the 11th hospital day showed
moderate diffuse thickening of the glomerular capillary walls without
proliferation or sclerosis; immunofluorescent staining was strongly
positive for IgG and complement, with lesser staining for 1gM. Electron
microscopy revealed numerous densely packed, moderately sized,
epimembranous deposits distributed diffusely and uniformly throughout
the glomerular capillary walls; diffuse fusion of epithellal cell foot
processes was evident. The pathologic diagnosis was membranous
glomerulonephritis.
The patient was treated with intravenous methylpredalsolone, 1 g
daily for 3 days, followed by oral prednisone, 30 mg each day for one
month. Prednisone then was stopped and chlorambucil, 10 mg dally,
begun. He was readmitted to the hospital 2 months later because of
symptomatic anemia; his hematocrit was 18.7%. At that time, he had
only 1 + pedal edema, and he was taking furosemide, 20mg twice daily;
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the creatinine clearance was 12 mI/mm. A 24-hour urine collection
contained 18 g of protein. No evidence of gastrointestinal bleeding was
found; the anemia was attributed in part to marrow suppression by
chlorambucil, and this drug was discontinued. He received another
course of intravenous methyiprednisolone followed by oral prednisone,
which was finally discontinued 2 months after the second hospital
admission. When last seen 4 months ago, the creatinine clearance was
57 mI/mm; urinary protein, 7.2 g/24 hi; serum albumin, 3.4 gIdl; and
serum cholesterol, 226 mg/dl. Only trace edema was present.
Discussion
DR. MICHAEL H. HUMPHREYS (Chief, Division of Nephrol-
ogy, San Francisco General Hospital, and Professor of Medi-
cine, University of California San Francisco, San Francisco,
California): This patient illustrates many of the key issues
regarding the development and management of nephrotic
edema. Although gratifying in this case, response of the under-
lying disease to treatment was the subject of a previous Ne-
phrology Forum [1], and I shall not consider it further today.
Rather, I shall focus on abnormalities in sodium handling in the
nephrotic syndrome, addressing first the mechanisms governing
fluid distribution across peripheral capillaries and the normal
defenses against edema, and then reviewing the evidence for or
against the two major hypotheses that have been offered to
account for the development of edema in proteinuric condi-
tions. In the process I shall discuss the roles of known sodium-
regulating systems in the context of these two hypotheses. I
shall then review some recent studies in experimental nephrotic
syndrome that suggest the possible cellular basis for nephrotic
sodium retention, and I shall conclude with a brief discussion of
some issues in the practical management of nephrotic edema.
Let us begin, then, by looking at normal defenses against
edema formation. The Starling equation relates the distribution
of fluid on two sides of a membrane to the hydrostatic and
oncotic pressure differences across the membrane:
J, = LP — oir
where J,. is the flow of fluid across the membrane; P and T,
the transmembrane hydrostatic and oncotic gradients, respec-
tively; L, the hydraulic conductivity of the membrane; and o
the Staverman reflection coefficient for plasma protein, chiefly
albumin. This relationship determines the balance of extracel-
lular fluid between the plasma compartment and the interstitial
space across peripheral capillary beds [2]. Increases in hydro-
static pressure, such as those that occur in the feet when one
changes from a lying to a standing position, favor the increase
in filtration of plasma water across capillaries. Normally, this
increase in capillary filtration does not lead to the accumulation
of excess interstitial fluid as edema because efficient mecha-
nisms remove the ifitered fluid, on the one hand, and retard its
formation, on the other. The increased filtration leads to an
increase in the flow of lymph and the return of fluid from the
lymphatic system to the circulation. Because the filtered fluid is
low in protein content, the concentration of albumin in the
interstitial fluid, normally about one-half that of the serum
albumin concentration, falls. This decrease increases the on-
cotic pressure gradient between plasma and interstitium, a
change that retards further filtration. The increased filtration
rate also increases interstitial hydrostatic pressure, thereby
offsetting the increase in capillary hydrostatic pressure that






Fig. 1. Overview of the development of edema in nephrotic syndrome
from underfihl mechanisms. In this model, nephrotic kidneys respond
normally to signals such as sympathetic nerve activity, the renin-
angiotensin system, and aldosterone, which are activated as a result of
a diminished plasma volume. These mechanisms then mediate second-
ary sodium retention.
filtration [3]. These mechanisms in aggregate prevent the devel-
opment of edema in day-to-day life in normal individuals. By
the same token, the occurrence of edema indicates that these
defenses have been disrupted at the local capillary level. In
addition, reduced renal sodium excretion relative to intake also
must be a major factor in states of generalized edema formation.
Underfihl edema in the nephrotic syndrome
Hypoalbuminemia is a hallmark of the nephrotic state, so
much attention has been focused on the role of reduced plasma
oncotic pressure in the edema of nephrotic syndrome (Fig. 1).
Hypoalbuminemia results both from a loss of albumin into the
urine, and from an increase in the fractional catabolic rate of
albumin [4]. Because albumin is the major contributor to plasma
oncotic pressure, a reduction in its concentration in plasma also
lowers plasma oncotic pressure. This in turn alters the Starling
forces governing the distribution of fluid between the plasma
and interstitial compartments: interstitial fluid volume increases
at the expense of plasma volume and, when the rate of capillary
filtration exceeds the ability of the mechanisms I have described
either to return it to the circulation or to retard its further
formation, edema develops. Just as in any condition of hypo-
volemia, the reduction in plasma volume then activates renal
sodium-conserving mechanisms. Renal sodium excretion is
reduced below that required to maintain sodium balance at the
given level of intake, and sodium is retained. This sodium
retention contributes directly to extracellular fluid volume
expansion and edema formation, and exacerbates the hypoalbu-
minemia. This hypothesis places primary emphasis on reduced
Glomerular Disease/
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serum albumin concentration and plasma volume in the process
of edema accumulation. According to this hypothesis, the
kidneys, functionally normal with respect to sodium metabo-
lism, respond appropriately to sodium-conserving stimuli acti-
vated by reduced plasma volume. I shall first review the data
supporting or refuting a critical role for each of the elements in
this proposed pathophysiologic scheme of nephrotic edema
formation.
Serum albumin concentration. A linchpin of the underfill
hypothesis is that a reduction in serum albumin concentration is
critical to the development of the edema. Support for this
concept stems from the clinical observation that virtually all
nephrotic patients with edema are hypoalbuminemic. However,
several lines of evidence suggest that hypoalbuminemia is not a
critical element in edema formation. Patients with analbumine-
mia (from congenital absence of the albumin gene) generally
have no gross abnormality in sodium homeostasis [5—7]; plasma
oncotic pressure is partially maintained by the presence of other
plasma proteins. Further, in analbuminemic rats, the transcap-
illary oncotic gradient does not markedly differ from normal [8].
Nor does capillary filtration differ markedly from normal [5],
and edema is only an occasional finding [6, 7]. The gradient
between plasma and interstitial fluid albumin or oncotic pres-
sure also has been examined when plasma albumin concentra-
tion has been reduced by plasmapheresis in animals with
normal kidneys. Manning and Guyton found that reduction of
plasma total protein concentration from 6.9 g/dl to 4.6 gldl,
corresponding to a reduction in plasma oncotic pressure from
21.6 mm Hg to 13.3 mm Hg, did not affect arterial pressure or
blood volume [9]. Additional plasmapheresis, which reduced
oncotic pressure to less than 6 mm Hg, reduced arterial
pressure and blood volume, and increased plasma renin activity
(PRA) [9]; the pattern of renal hemodynamic function was
consistent with renal hypoperfusion [10]. Wraight observed that
the transcapillary escape rate of albumin, a measure of its
permeability across peripheral capillary beds, decreased when
plasma albumin was lowered by plasmapheresis from 2.12 g/dl
to 1.36 g/dl in rats [11]. Such a result would favor the mainte-
nance of a normal or near-normal oncotic gradient across the
capillary wall in hypoalbuminemic states. A similar approach in
dogs, however, failed to demonstrate a decrease in the trans-
capillary escape rate of albumin after plasmapheresis, but did
show that reduction of plasma oncotic pressure to 9 mm Hg did
not decrease blood volume or increase PRA or plasma aldoste-
rone concentration [12]. A further reduction in oncotic pressure
to 7.3 mm Hg led to transient sodium retention and elevations in
PRA and plasma aldosterone concentration [12]; this result was
similar to the findings of Manning and Guyton [9, 10]. As is true
in analbuminemic rats, the transcapillary oncotic gradient was
preserved during plasmapheresis by a parallel reduction in
tissue oncotic pressure as plasma oncotic pressure fell, except
at the very lowest levels of plasma oncotic pressure, when the
interstitial fluid oncotic pressure no longer declined [121. The
data thus suggest that hypoalbuminemia in humans or animals
with normal kidneys does not necessarily result in fluid reten-
tion and plasma volume contraction unless plasma oncotic
pressure falls dramatically to less than 8 mm Hg or so.
Numerous clinical and experimental observations call into
question a key role for hypoalbuminemia in the pathogenesis of
nephrotic edema. Kaysen and associates demonstrated that rats
with Heymann nephritis, a model of human membranous ne-
phropathy, had plasma and extracellular fluid volumes no
different than did normals despite a reduction in plasma oncotic
pressure from 20 mm Hg to 9 mm Hg [13]. Administration of
albumin concentrates does not appreciably mobilize edema
fluid in many nephrotic subjects [14, 151, although sodium
excretion can increase transiently in some [16—18]. Finally,
patients with minimal-change nephropathy who are treated with
corticosteroids undergo a diuresis and natriuresis well before
the serum albumin concentration starts to increase; this finding
suggests that correction of the hypoalbuminernia might not be
important in the steroid-induced natriuresis [19, 20]. In aggre-
gate, then, a compelling role for reduced plasma albumin
concentration and oncotic pressure in the sodium retention of
nephrotic syndrome is difficult to demonstrate.
Plasma volume. Another critical concept in the underfill
hypothesis of nephrotic edema formation is that plasma volume
contraction is the proximate stimulus for renal sodium reten-
tion. This concept derives closely from the importance of the
hypoalbuminemia: the reduction in plasma oncotic pressure
that accompanies the hypoalbuminemia alters the Starling equa-
tion in a manner that favors the transfer of plasma water into the
interstitium. Early observations suggested that hypovolemia
was indeed a prominent feature of the nephrotic state, even to
the point of producing circulatory collapse and acute renal
failure [21]. However, the basis for the renal failure in many of
these cases might be due to factors other than hypovolemia and
renal hypoperfusion [15]. The technique of plasma volume
measurement in hypoalbuminemic subjects came into question
following the observation that postural reductions in plasma
volume were exacerbated in hypoalbuminemic patients [22, 23].
A survey of clinical measurements of plasma volume in ne-
phrotic patients found a lack of uniformity in the results:
although some observations did indicate a significant reduction
in plasma volume, a majority of patients were found to have
normal plasma volume measurements, and some actually had
increased plasma volume [24]. This same group also published
in 1984 an extensive review on the role of plasma volume in
nephrotic edema formation [151. They performed a detailed
critique of the technique of plasma volume measurement, and
they concluded that methodologic considerations could intro-
duce an error of only a few percent in the measurement, an
amount not adequate to account for the wide range of measure-
ments observed in clinical studies including the preponderance
of normal or increased values in nephrotic patients [15, 25].
Results of plasma volume measurements in animals with exper-
imental nephrotic syndrome likewise do not demonstrate a
reduced plasma volume [13, 26].
If reduced plasma volume were a critical factor in nephrotic
sodium retention, one would expect that correction of the
hypovolemia by plasma volume expansion would lead to natri-
uresis. Indeed, early studies showing a benefit of plasma
expansion therapy on natriuresis in nephrotic subjects provided
initial support for underfill mechanisms [17, 18]. This viewpoint
is also supported by more recent data [16] and by the studies by
Usberti et al, who showed that impaired water excretion in a
group of nephrotics with reduced plasma volume was improved
by infusion of hyperoncotic albumin, which reduced the plasma
ADH concentration [27]. They concluded that hypovolemia in
these subjects led to nonosmotic stimulation of ADH secretion,
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which was corrected by the volume expansion [27]. Other
studies evaluating the response to plasma volume expansion
have indicated that expansion does not uniformly lead to
natriuresis [14, 28]. Several studies have shown that central
blood volume expansion produced by head-out water immer-
sion could induce natriuresis in nephrotic subjects [29—33].
These studies did not always establish whether the natriuretic
response was as potent as expected in normal individuals or
was blunted; in the study by Krishna and Danovitch, the
magnitude of the natnuresis during immersion significantly
correlated with the initial plasma volume [30]. This association
suggested that diminished plasma volume contributed to
blunted natriuresis in some patients [30]. More recently, Peter-
son and colleagues used the same technique and also found a
blunted response by nephrotic subjects compared to normals;
these observations suggested that, despite equivalent degrees of
central blood volume expansion, the nephrotic patients had
impaired natriuresis [321. Remission of steroid-responsive ne-
phrotic syndrome also has not been associated with an increase
in plasma volume [24].
Thus, as is the case with hypoalbuminemia, the evidence
supporting a key role for plasma volume contraction in the
development of nephrotic edema is lacking. The reason for the
preservation of plasma volume in many nephrotic patients,
despite the marked reduction in plasma albumin concentration
and oncotic pressure, is that interstitial oncotic pressure is
reduced in parallel, thus maintaining the transcapillary oncotic
gradient 1T [34—36]. Only when plasma oncotic pressure is
profoundly reduced (below 8 mm Hg) is the gradient seriously
affected, and it is at this level that evidence of hypovolemia can
appear [9, 10, 34].
The renin-angiotensin-aldosterone system. Because underfill
states of any cause initiate sodium retention through common
pathways, these pathways also have been studied intensively to
evaluate their roles in nephrotic edema; the renin-angiotensin-
aldosterone system is foremost among them. Aldosterone ini-
tially was isolated from the urine of children with nephrotic
syndrome [37], thus suggesting its importance in this condition.
Plasma renin activity, the focus of much attention, has been
measured in many series. Unfortunately, the results are incon-
clusive: although elevated in some patients, values are normal
in others and suppressed in still others [14, 16, 19, 20, 23, 24, 27,
28, 30, 31, 33]. Medina and colleagues suggested that low levels
of PRA could reflect a depletion of renin substrate [38]. This
possibility was evaluated directly by Boer and associates, who
found that renin substrate concentration was normal or elevated
in 25 of 27 cases of nephrotic syndrome [39]. In these patients,
PRA was low or normal in 24 of the 27, indicating that substrate
depletion did not lead to spuriously low values of PRA, and
implying that variations in PRA in nephrotic patients reflected
factors other than volume status.
Since static measurements of PRA by itself do not give much
insight into the role of the renin-angiotensin system in nephrotic
edema, the functional responsiveness of this system has been
studied during volume expansion with albumin infusions or
head-out water immersion. Albumin infusion regularly sup-
presses PRA, usually without regard to the initial magnitude of
the PRA [14, 16, 27]. Central blood volume expansion produced
by head-out water immersion also suppresses PRA in nephrotic
patients [30, 31, 33]. The functional significance of these obser-
vations is unclear, however. Although these maneuvers can
increase sodium excretion, the relationship of the suppression
of PRA to the natriuresis is not established. As I already
mentioned, Peterson et al observed that head-out water immer-
sion resulted in blunted natriuresis in nephrotics [32]. Although
PRA was not measured in these studies, it is likely that it
decreased, as reported by others [30, 31, 33]. Dietary salt
loading was successful in suppressing PRA in 2 nephrotic
patients, but sodium retention and weight gain were the same as
in 8 other subjects whose PRAs were not suppressed [40].
Infusion of the angiotensin II receptor antagonist saralasin into
6 nephrotic patients failed to increase sodium excretion; indeed,
at the higher infusion rates, sodium excretion was actually
decreased, perhaps because of a concomitant fall in GFR [41].
Brown and associates identified a group of 12 nephrotic patients
in whom PRA inversely correlated with serum albumin concen-
tration [42]. This finding would be expected if hypoalbuminemia
leads to hypovolemia, which then stimulates renin secretion.
However, blockade of the renin-angiotensin system with cap-
topril in 8 nephrotic patients with elevated PRA did not alter
sodium retention or lead to natriuresis as it did in normal
subjects [27]. This observation suggests that sodium retention
in the nephrotic patients was not under control of the renin-
angiotensin system.
The response of PRA to steroid therapy of the nephrotic
syndrome likewise calls into question the importance of this
system in nephrotic edema formation. In a group of patients
with minimal-change nephropathy with normal or low PRA,
Dorhout Mees and associates observed no overall change in
PRA after steroid-induced remission, although PRA tended to
increase while blood pressure fell significantly; these changes
are not consistent with underfill mechanisms [24]. In contrast,
Brown et al found that PRA fell from high levels in selected
patients with minimal-change lesions during remission, but then
rebounded to elevated values. These investigators concluded
that elevated renin and aldosterone levels were not related to
nephrotic sodium retention [19], although the fall in PRA and
plasma aldosterone did correlate with steroid-induced natriure-
sis. Koomans and colleagues also observed reductions in PRA
and plasma aldosterone concentration in patients with minimal-
change nephropathy undergoing steroid-induced remission, but
concluded that the changes in PRA were a consequence of
improved filtration and delivery of sodium to the macula densa
with suppression of renin secretion, rather than a result of
correction of a diminished plasma volume [20]. Using data from
their studies of PRA, Meltzer and colleagues identified two
types of nephrotic patients. The first group was a vasoconstric-
tor type with high PRA, plasma volume contraction, and
elevated hematocrit consistent with hemoconcentration; mini-
mal-change nephropathy was evident on renal biopsy. The
second type comprised hypervolemic patients characterized by
increased plasma volume, reduced hematocrit, and a sup-
pressed PRA; they had membranous or membranoproliferative
nephropathy and reduced GFR [43]. These authors suggested
that measurement of PRA could help delineate two different
pathophysiologic mechanisms of nephrotic edema. On the other
hand, Geers and associates examined the relationships among
plasma volume, PRA, and renal function in a large group of
patients with both minimal-change lesions and a variety of other
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glomerular abnormalities [44]. Their failure to find any signifi-
cant differences between patients with minimal-change ne-
phropathy and those with histologic lesions fails to confirm the
hypothesis of Meltzer et al.
In aggregate, there seems to be no consensus regarding the
role of PRA in nephrotic edema formation or in the resolution of
the edema. This should not be surprising, as renin secretion
might be under the direct influence of local, intrarenal pathways
related to the intrinsic renal disease as well as systemic factors
reflecting blood volume status; the latter might be more impor-
tant in minimal-change nephropathy.
Similar ambiguity attends the role of aldosterone in the
pathogenesis of nephrotc edema. In many of the PRA studies I
just reviewed, either plasma aldosterone concentration or uri-
nary aldosterone excretion also was measured [14, 16, 19, 20,
27, 29, 31, 33]. However, as was true with PRA, no consensus
exists that aldosterone levels are increased in nephrotic sub-
jects nor that mineralocorticoid effects are important in ne-
phrotic sodium retention. Brown and associates administered
the converting enzyme inhibitor captopril to a group of ne-
phrotic patients with initially elevated PRA and plasma aldo-
sterone [28]. Captopril lowered plasma aldosterone concentra-
tion and blood pressure, but did not cause natriuresis or prevent
further weight gain. This same group examined the relationship
between plasma aldosterone and sodium excretion in a group of
patients with minimal-change disease during steroid-induced
remission; the observation that plasma aldosterone fell as
diuresis and natriuresis developed suggested that the hormone
could have participated in the initial sodium retention [19].
Koomans et al also found a reduction in plasma aldosterone
concentration, albeit a statistically insignificant one, during the
induction of remission by steroid administration, but they
argued that this reduction was not the basis for the natriuresis
[20]. On the other hand, Shapiro et al administered the aldoste-
rone antagonist spironolactone to a group of 5 nephrotic pa-
tients with membranous nephropathy or focal glomerulosclero-
sis [45]. These patients were in positive sodium balance while
ingesting a high-sodium diet, but went into negative sodium
balance when treated with spironolactone. The authors con-
cluded that aldosterone was an important factor in nephrotic
sodium retention. However, the plasma aldosterone concentra-
tions did not differ in the patients compared with a group of
normal subjects treated in a similar manner. This similarity
suggests the possibility of increased sensitivity to aldosterone in
the nephrotics via an as-yet-unexplained mechanism [45]. That
rats with experimental nephrosis develop edema that is main-
tained despite adrenalectomy [26] indicates that sodium reten-
tion in these animals does not require aldosterone.
The sympathetic nervous system. The sympathetic nervous
system is another homeostatic system activated during hypo-
volemia. Other states of pathologic sodium retention, namely,
congestive heart failure and cirrhosis of the liver, are associated
with heightened sympathetic nervous system activity [46, 47],
thought to reflect the functional response to an underfilled
circulation. If underfill mechanisms also operate in nephrotic
sodium retention, sympathetic activation likewise should exist.
Oliver et al measured urinary catecholamine excretion in a
group of nephrotic children. Catecholamine excretion was
elevated in a manner roughly paralleled by the sodium avidity of
these patients, but fell to normal levels within a few days of
steroid treatment and before proteinuria or sodium retention
had resolved [48]. The same investigators also measured plasma
norepinephrine; in nephrotic children excreting less than 1
mEq/day of sodium, the concentration was elevated over that in
normal children, but plasma norepinephrine was no different in
nephrotics excreting more than 10 mEq/day of sodium [49].
Plasma volume expansion successfully lowered norepinephrine
levels in nephrotic children [16, 49]. Subsequent measurements
of plasma norepinephrine have yielded conflicting results.
Dorhout Mees and colleagues found no difference in either
supine or upright levels between normal subjects and patients
with nephrotic syndrome [15, 23]. On the other hand, a prelim-
inary report of norepinephrine kinetics in supine nephrotic
patients found a greater rate of norepinephrine secretion com-
pared with controls, and this increased norepinephrine secre-
tion led to a marginally greater plasma norepinephrine concen-
tration. However, nephrotic patients had insignificant increases
in these variables with upright posture as opposed to greater,
significant increases in the normal subjects [50].
An important role for renal nerves in nephrotic sodium
handling has been shown in studies examining the response of
rats with experimental nephrosis to oral and intravenous so-
dium loading [51]. Conscious nephrotic rats had blunted natri-
uresis to oral sodium loads that was corrected by renal dener-
vation. Compared with normals, efferent sympathetic renal
nerve activity was higher in nephrotic rats, and decreased less
after intravenous volume expansion [51]. On the other hand, we
were unable to demonstrate improvement in volume expansion
natriuresis in anesthetized, nephrotic rats [52].
These studies indicate some variability in the extent of
sympathetic nerve activation in nephrotic syndrome and, like
the other measures that have been used to assess arterial
underfilling, indicate that the available data do not permit a
conclusion that nephrotic edema arises from underfill mecha-
nisms.
Overflow mechanisms of nephrotic edema
Because of the difficulties in painting a uniform picture of an
underfill state in most nephrotic patients, it is not surprising that
researchers have developed an alternative hypothesis. In con-
trast to underifil edema, this hypothesis regards sodium reten-
tion leading to edema as a result of a primary intrarenal
abnormality. In addition to being supported by the data I
reviewed that are inconsistent with underfill mechanisms, the
overflow hypothesis is also buttressed by direct observations
indicating the presence of an intrarenal sodium handling defect.
The resulting overflow edema is summarized in Figure 2.
According to this hypothesis, proteinuric renal disease leads to
increased reabsorption of filtered sodium, chiefly in the distal
nephron, through mechanisms that have been only partially
identified. In addition, decreased GFR from glomerular injury
also can contribute to sodium retention [53]. With continued
ingestion of sodium in excess of renal excretory ability, extra-
cellular fluid and blood volume expand. In the context of the
Starling equation, increased capillary filtration takes place
primarily by an increase in P to the point that the defenses are
overcome and edema accumulates.
Direct evidence supporting this form of nephrotic edema
formation began to accumulate with the observation that in
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Primary Renal
Sodium Retention
Fig. 2. Representation of nephrotic edema formation from overflow
mechanisms. In this model, hypoalbuminemia is not a critical compo-
nent of sodium retention; rather, proteinuric renal disease leads to
heightened sodium reabsorption through a primary, intrarenal mecha-
nism, the basis for which is not currently understood, but which is
independent of the renin-angiotensin system and other pathways of
secondary sodium retention.
dogs with unilateral glomerulonephntis, abnormal sodium han-
dling occurred only in the affected kidney [54]. Induction of
unilateral proteinuria by the intrarenal administration of amino-
nucleoside of puromycin also led to sodium retention by the
proteinuric kidney [55, 56]. The mechanism leading to this
unilateral sodium retention might relate to the reduced GFR
resulting from puromycin administration [55, 56]. However,
micropuncture experiments indicated that, despite reduced
GFR, delivery of filtrate to the distal nephron was similar in
control and nephrotic kidneys; this observation led to the
conclusion that increased sodium reabsorption in the late distal
nephron was responsible for the unilateral sodium retention
[56]. This conclusion agrees with the earlier experiments by
Bernard and associates, who also found evidence for increased
distal sodium reabsorption in rats with Heymann nephritis [57],
and with clinical studies by Grausz et a! 20 years ago, who
concluded that reabsorption in the proximal tubule was de-
creased in sodium-retaining nephrotic patients, thus indicating
that increased distal reabsorption must have occurred [58].
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Fig. 3. Response of plasma ANP concentration to head-out water
immersion in normal subjects and in patients with nephrotic syndrome.
Plasma ANP concentration was lower in nephrotic patients (solid
circles) than in normals (open circles) at the outset, but rose to levels
slightly higher than in normals after 3 hours of immersion. Despite this,
nephrotic patients had a blunted natriuretic response. *, significantly
greater than time 0; +, significantly less than value in normals, P < .05.
(From Ref. 32.)
nephrotic sodium handling, reduced GFR, and increased distal
sodium reabsorption. The reduction in GFR presumably results
from structural glomerular damage but could also reflect hypo-
perfusion: Shapiro et al showed that impaired water excretion
in a group of nephrotic patients could be related to a reduced
GFR [59]. Water immersion improved renal water excretion in
a manner that correlated best with the observed increase in
GFR [59]. The mechanism underlying heightened reabsorption
in the distal nephron is not known with certainty, but it could
relate to impaired action of atrial natnuretic peptide (ANP).
In addition to exhibiting blunted volume-expansion natriure-
sis, it was quickly observed that nephrotic animals and most
nephrotic patients have appropriately elevated plasma ANP
concentrations after volume expansion [16, 31, 32, 52, 60]. Thus
the nephrotic state was defined as a condition of ANP resis-
tance. In the study by Peterson and colleagues, a 3-hour period
of head-out water immersion in a group of nephrotic patients
caused plasma ANP concentration to increase from 14 3
pg/mi to 75 19 pg/mi, a value slightly higher than that in
normal control subjects (Fig. 3) [32]. Yet increases in both
fractional and absolute rates of sodium excretion were mark-
edly blunted in the nephrotic patients, so it is likely that these
patients had renal resistance to ANP [32]. This suggestion is
further supported by experiments of ANP infusion into ne-
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Fig. 4. Natriuretic effect of intravenous ANP infusion in rats 21 days
after one kidney was rendered proteinuric by the intrarenal administra-
tion of adriamycin (ADR). Proteinuric kidneys (solid circles) had an
absent natruretic response to the infusion, whereas control kidneys
(open circles) in the same animals exhibited the expected natriuresis
(top panel). Injection of the saline vehicle alone did not alter ANP
responsiveness (bottom panel). (From Ref. 64.)
or absent compared with the response in normal animals
[61—63]. This blunted ANP responsiveness resided within the
kidney; rats with unilateral proteinuria from administration of
adriamycin into one renal artery exhibited resistance to sys-
temic ANP infusion in the proteinuric kidney, while the non-
proteinuric, contralateral kidney was normally responsive to
ANP [64] (Fig. 4). The resistance to ANP did not appear to be
due to altered binding of the peptide to its receptors in the inner
medulla [64], but was improved by renal denervation [611. This
latter observation suggests that ANP resistance is related to the
heightened efferent renal sympathetic nerve activity in ne-
phrotic animals [511. This conclusion was strengthened by the
finding that stimulation of renal nerves in normal rats blunted
the renal response to ANP infusion [65]. The possibility that
this ANP resistance in nephrotic patients could account for the
blunted response to volume expansion was, therefore, an
attractive idea to pursue. We have measured the renal response
to volume expansion in rats with high-grade proteinuria from
adriamycin administration [52]. This agent produces proteinuria
without marked reduction in GFR in the early stages; later,
GFR falls, and focal glomerulosclerosis develops [66]. Rats
with adriamycin-induced nephrosis had blunted natriuresis in
response to volume expansion despite plasma concentrations of
ANP that were actually higher than those seen in normal rats
undergoing the same volume-expansion protocol (Fig. 5). The
blunted natriuretic response was accompanied by a parallel
blunting of the increase in urinary cyclic guanosine-3' ,5'-mono-
phosphate (cGMP) excretion (UCGMPV) (Fig. 5); UCGMPV is a
useful index for the renal actions of ANP [67]. Thus, blunted
natriuresis in response to volume expansion in these nephrotic
animals was related to ANP resistance, which in turn was
linked to an abnormality in cGMP metabolism [52].
The cellular basis for nephrotic ANP resistance was explored
in additional experiments by our group. Figure 6 is a schematic
view of ANP's effects on its target cell, in this case an epithelial
cell in the inner medullary collecting duct (IMCD), a recognized
site of ANP action [68]. The secreted peptide must reach its
receptors via a blood-borne route. Once there, it interacts with
its receptor. Although several classes of receptors for ANP
have been described [69], those in the IMCD are primarily of
the biologically active type containing guanylate cyclase activ-
ity in the intracellular domain of the receptor [70]. Interaction of
ANP with these receptors activates the guanylate cyclase to
increase the production of cGMP. The intracellular second
messenger, cGMP, then causes, either directly or through
intermediary steps, a luminal membrane amiloride-sensitive
sodium channel to close, thereby inhibiting sodium reabsorp-
tion [68]. The signal is terminated by cleavage of cGMP to
5'GMP, chiefly by the action of a specific cGMP phosphodies-
100 terase (PDE). The ANP resistance in nephrosis could result
from a failure of normally secreted peptide to gain access to its
receptors in the IMCD, impaired binding to these receptors,
impaired generation of cGMP, or accelerated breakdown of
normally produced cGMP.
To test these various possibilities, we measured ANP-depen-
dent cGMP accumulation in vitro in glomeruli and IMCD cells
isolated from normal and nephrotic rats (Fig. 7). We observed
blunted cGMP accumulation in both tissues in response to
increasing concentrations of ANP. Thus ANP resistance in vivo
was unlikely to result from impeded access of the peptide to its
receptors [52]. Binding of ANP to IMCD cells did not differ
between normals and nephrotics, as previously shown by
Perico et al [64]. Therefore, we examined the effect of PDE
inhibition on ANP-dependent cGMP accumulation in vitro. In
the presence of the nonselective PDE inhibitor 3-isobutyl-l-
methylxanthine (IBMX), basal cGMP accumulation both by
isolated glomeruli and IMCD cells increased, and the difference
between normal and nephrotic tissues in response to ANP was
no longer observed. These results were extended by using a
specific cGMP PDE inhibitor zaprinast (M&B 22,948) (Fig. 7).
The effect of this compound on basal cOMP accumulation was
modest, and ANP increased cGMP accumulation in a dose-
dependent manner. However, as with IBMX, the difference
between normal and nephrotic rats was no longer apparent [52].
In aggregate, these results suggest that the abnormality in
nephrotic cGMP metabolism could be related to heightened
activity of cGMP PDE. This possibility was further supported
by experiments measuring cGMP accumulation in response to
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Fig. 6. Schematic representation of the steps in ANP signaling in a cell
from the inner medullary collecting duct.
cyclase not linked to the ANP receptor. If cells from nephrotic
animals had heightened activity of cGMP PDE, cGMP accumu-
lation in response to this compound should also be blunted.
This was indeed the case and, as with ANP-dependent cGMP
accumulation, the difference between accumulation by normal
and nephrotic glomeruli and IMCD cells in response to nitro-
prusside was abolished by IBMX and zaprinast [52]. To test the
physiologic relevance of these in-vitro findings, we infused
zaprinast continuously into one renal artery of normal and
nephrotic rats in a dose that had no effect on basal sodium
excretion or UCGMPV. In nephrotic rats, volume expansion
produced the same blunted natriuretic response by contralat-
eral, noninfused kidneys as previously observed. Nephrotic
kidneys infused with zaprinast exhibited a natriuretic response
that was indistinguishable from the response by normal rat
kidneys, however. The zapnnast infusion also normalized the
Fig. 5. Effect of intravenous normal saline
volume expansion (2% body weight over 5 mm
[shown by the black bar]) on sodium excretion
(A) and cyclic GMP excretion (B) in normal
and nephrotic rats. Nephrotic rats (triangles)
had a blunted natriuretic response that was
accompanied by a smaller increase in UCOMPV
in response to the volume expansion
compared to normal rats (circles). (From Ref.
52 with permission of the American Society of
Clinical Investigation.)
increase in UCGMPV after volume expansion by nephrotic
kidneys [52]. Thus, this cGMP PDE inhibitor was able to
correct not only ANP resistance shown by nephrotic cells
in vitro, but it also corrected the blunted volume-expansion
natriuresis in nephrotic rats in vivo. These results raise the
possibility that abnormal sodium metabolism in nephrosis is
related to a specific cellular alteration in the ANP signaling
pathway, namely, an increase in cGMP PDE activity that blunts
the cellular actions of cGMP normally produced in response to
ANP's interaction with its biologically active receptor. This
possibility was extended by preliminary data from our group,
which showed that rats with Heymann nephritis also had
cellular resistance to ANP that was corrected by zaprinast [71].
This latter observation implies heightened cGMP PDE activity
in this form of proteinuric renal disease also.
Not all results support the argument that increased activity of
cGMP PDE ultimately accounts for abnormal nephrotic sodium
metabolism. Abassi et al measured UCGMPV during ANP infu-
sion and found no difference between normal rats and rats with
adriamycin-induced nephrosis [72]. However, data were ex-
pressed per unit of GFR; since the nephrotic rats had lower
GFR, absolute UCGMPV by nephrotic animals was only 55% the
value in normals, a reduction qualitatively similar to the differ-
ence observed by Valentin and associates after volume expan-
sion in rats in which differences in GFR were much smaller [521.
Woolf et al infused ANP into a heterogeneous group of ne-
phrotic patients and found no difference in either the natriuresis
or the increase in UCGMPV from normal subjects [73]. In this
group of nephrotic patients, only 3 of 6 actively retained sodium
on a dietary intake of 150 mmoLlday; the normal natriuretic
response of the group as a whole suggests that they did not have
ANP resistance. However, the peak UCGMPV by the nephrotic
patients of only 56% of normals during ANP infusion again
suggested blunted responsiveness to the peptide [73].
Underfihl versus overflow
Given this wealth of contradictory clinical and experimental



















edema formation? As I said earlier, one important issue lies in
the credibility of plasma volume measurement in nephrotic
syndrome; in addition to artifacts introduced by differences in
posture and in the transcapillary escape rate of albumin, there is
also some ambiguity in the proper reference to express the
result. Because nephrotic patients are by definition edematous,
so-called "dry weight" can be determined only after the fact, if
at all, and thus an appropriate reference is difficult to identify [9,
74]. Even so, the differences in clinical and experimental
studies are such that instead of facing an "either/or" situation,
we could be dealing with one that is "both. . . and"; that is,
features of both underfill and overflow mechanisms might
contribute to the pathogenesis of edema in nephrotic patients
[9, 74]. In this formulation, a common thread of all nephrotic
states could be an intrarenal sodium handling abnormality, one
perhaps related to ANT' resistance. This abnormality leads to
positive sodium balance and edema formation on an overflow
basis, but can be modified in its manifestations by underfill
features, which would result from the severity of the hypoalbu-
minemia; patients with plasma oncotic pressures less than 8 mm
Hg would be particularly likely to exhibit evidence of underfill.
Additionally, some have suggested that nephrotic patients have
a widespread abnormality in capillary permeability that could
lead to reductions in plasma volume [27, 75]. Drawing on the
initial hypothesis of Shalhoub that minimal-change nephropathy
reflects a disorder of T-cell function [76], Lagrue et al found that
cultures of lymphocytes from nephrotic patients, when stimu-
lated with concanavalin.A, released a substance resembling a
cytokine into the medium that increased vascular permeability
when tested in a skin extravasation bioassay [77]. Underfill
manifestations could predominate in individual patients to the
extent that the one or more factors responsible for this abnor-
mality were activated. Although the concept of a widespread
permeability defect in minimal-change nephropathy has been a
controversial one [78], such an abnormality could help explain
why most data indicating underfill mechanisms have been
obtained in patients with this form of nephrosis.
The sodium-retaining pathways activated by an underfilled
circulation could themselves possibly initiate an intrarenal
sodium reabsorptive abnormality characterized by renal resis-
tance to ANP similar to the scheme I have outlined. Cells of the
IMCD exhibit specific binding and/or physiologic actions to a
number of neurohumoral compounds involved in epithelial
solute and water transport; in addition to ANP, these include
vasopressin [79], angiotensin II [80], endothelin [81], aldoste-
rone [82], ct-adrenergic agonists [83], and adenosine [841. Acti-
vation of one or more of these regulatory systems by an
underfilled circulation could lead to the development of tubular
resistance to ANP throughthe mechanism I described. Figure 8
is a schematic representation of how overflow and underfill
mechanisms each might bring about ANP resistance through an
increase in cGMP PDE activity.
Thus, it seems possible that underifil and overflow mecha-
nisms interact with each other in the production of nephrotic
edema. The extent of this interaction will determine the char-
acteristics of sodium and volume regulation in individual pa-
tients. It is clear that more work is required to elucidate the
nature of this interaction.
Management of nephrotic edema
Given these complexities regarding the pathophysiology of
nephrotic edema formation, it is no surprise that its manage-
ment is frequently problematic. Table 1 lists measures that can
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Fig. 7. ANP-dependent cGMP accumulation
by isolated glomeruli (left) and IMCD cells
(right) from normal (circles) and nephrotic
(triangles) rats. Nephrotic tissues had a
markedly blunted response compared to
normals (top panels). Addition of the specific
cGMP phosphodiesterase inhibitor zaprinast
(M&B 22,948, iO M) did not alter basal
levels appreciably, but normalized
responsiveness by the nephrotic cells (bottom
panels). Asterisks indicate nephrotic values
significantly less than normals (P < .05 or
greater). (Modified from Ref. 52.)










Fig. 8. Hypothetical scheme whereby both
underfihl and overflow mechanisms result in
ANP resistance in IMCD cells. An underfilled
circulation could activate a number of neural
and humoral pathways, a few of which are
depicted here, to act on the IMCD cell to
increase cGMP phosphodiesterase activity,
thereby producing ANP resistance. Overflow
mechanisms could have the same result,
although the signal responsible for increasing
cGMP PDE activity has not yet been
identified.








sodium restriction is a mainstay in the approach to all condi-
tions of generalized edema formation. Many nephrotic patients
in the active stages of sodium retention will excrete less than 10
mEq of sodium per day. Because reduction of sodium intake to
this level or less is extremely difficult to achieve outside a
metabolic ward, sodium restriction to the more modest levels
achievable in the outpatient setting is usually helpful only in
slowing the rate of edema formation rather than in leading to its
resolution. However, many nephrotic patients with edema will
be less sodium avid, as illustrated in some of the clinical studies
I discussed earlier [19, 20, 27, 30, 45, 73]. In these patients,
rates of sodium excretion match levels easily achieved with
modest sodium restriction, and positive sodium balance occurs
only when they are challenged with excessively high sodium
intakes. Therefore, dietary sodium restriction to about 50
mEq/day should be a reasonable goal in all patients.
Bed rest is another measure of general benefit in edematous
disorders, presumably because it alleviates orthostatic activa-
tion of the renin-angiotensin and sympathetic nervous systems
that accompany upright posture, and facilitates the transfer of
interstitial fluid to the vascular compartment to expand central
blood volume. But bed rest obviously is of limited practical
utility, and its benefits must be balanced against its risks;
hypercoagulability is a feature of most nephrotic patients and
increases the risk of thromboembolic complications, especially
with prolonged bed rest [85]. Support stockings are also of some
use; by favoring the distribution of blood to the central blood
volume, they may alleviate some of the stimuli for sodium
retention [86] in a manner analogous to the effects of head-out
water immersion. As I said earlier, this maneuver increases
sodium excretion in nephrotic patients through central blood
volume expansion, stimulation of ANP release, and suppres-
sion of PRA and plasma aldosterone [29—33]. It, too, is of only
limited practicality as a diuretic technique; moreover, sodium
excretion decreases to basal values immediately alter patients
are removed from the immersion tank, and it is possible that
even more avid sodium retention during the time out of the tank
offsets the natriuresis occurring as a result of the immersion.
Plasma volume expansion, usually with hyperoncotic albu-
min concentrates, is an oft-tried approach to nephrotic edema.
The data I summarized earlier indicate that results with this
approach are variable, with less than one-half of patients
responding [16—20, 27, 28]. However, volume expansion ther-
apy might play an adjunctive role in the diuretic management of
nephrotic patients who have resistant edema; plasma expansion
restored responsiveness in a group of such patients [87]. The
major drawback with this approach is that the infused albumin
is rapidly excreted into the urine [88] by an apparent increase in
glomerular pore size [89]. This makes albumin administration
an expensive therapy with only short-lasting benefit, and there-
fore it should be reserved for patients with only the most
resistant, severe, symptomatic edema.
Diuretics are of course the cornerstone of management of
nephrotic edema. Loop diuretics are generally employed be-
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action, although Shapiro and associates showed that the aldo-
sterone antagonist spironolactone exerted at least a short-term
natriuretic effect in a group of nephrotic patients on a high-
sodium diet [45]. Diuretic efficacy in nephrotic patients results
from factors determining pharmacokinetics and pharmacody-
namics. Brater has suggested that the ratio of urinary sodium
excretion to urinary diuretic excretion is a useful indicator of
diuretic potency [90], and in micropuncture studies, Kirchner,
Voelker, and Brater showed that the reduced ratio in nephrotic
rats was related to a blunted effect of intravenous furosemide on
loop chloride reabsorption [91]. These authors proposed that
furosemide resistance in nephrotic syndrome was caused by
binding of the diuretic to tubular fluid albumin. The addition of
albumin to tubular fluid of normal rats reproduced the nephrotic
defect [92], and agents such as sulfisoxazole, which competed
with furosemide for albumin binding, restored responsiveness
[93]. If these observations hold true in humans with nephrosis,
as seems likely, higher doses of furosemide to overcome
binding of the drug to tubular fluid albumin likely will be
required to achieve a desired diuretic effect [90]. Continuous
infusion of the loop diuretic bumetanide in patients with chronic
renal insufficiency has greater diuretic potency than does the
same total dose of drug given intermittently [94]. It is possible
that continuous infusion also is more potent in nephrotic
patients with preserved GFR as well, although this point has not
been specifically addressed. Impaired absorption of orally ad-
ministered diuretics because of edema of the bowel wall might
reduce the drug's bioavailability and limit its diuretic effect [95].
Finally, ultrafiltration has been suggested as an alternative
approach in diuretic-resistant nephrotic patients with massive
edema [96]. This technique is offered to hospitalized patients in
the critical care setting, many of whom have acute renal failure
[97], and obviously can be recommended only in the most
exceptional cases. It has been suggested that renal failure in
some nephrotic patients develops from intrarenal edema caus-
ing a reduction in GFR [98]. Although such cases are difficult to
recognize, ultrafiltration might have some utility in their man-
agement.
Questions and answers
DR. FLOYD C. RECTOR, JR. (Chairman, Department of Med-
icine, University of California San Francisco, San Francisco,
California): A variety of models of hypovolemia involve acti-
vation of the sympathetic nervous system and the remn-angio-
tensin-aldosterone axis. Have you had the opportunity to look
at the effects of any of these models, such as chronic salt
depletion, on the activity of the cGMP phosphodiesterase?
DR. HUMPHREYS: That's a very good question. One would
predict that any circumstances that led to activation of the
pathways outlined on the left side of Figure 8 might be accom-
panied by ANP resistance. No studies have specifically ad-
dressed this issue. As with any natriuretic stimulus, the magni-
tude of the response to ANP is conditioned by the levels of
counterregulatory systems like renal sympathetic nerves and
angiotensin II [65, 99]. However, I am not aware of any data
suggesting that this blunted action is related to the cellular
mechanism that I outlined. Abassi et al demonstrated reduced
excretion of cGMP in rats with high-output heart failure [100];
these findings are similar to our observations in experimental
nephrotic syndrome in rats [52]. Abassi's group found cGMP
accumulation in response to ANP in glomeruli isolated from
these rats to be the same as that in normals when incubated in
the presence of IBMX, but they did not study glomeruli without
this PDE inhibitor, so a difference might have been missed. On
the other hand, abnormal binding of ANP in renal medulla of
rats with heart failure has been demonstrated [101], and blunted
ANP-dependent cGMP accumulation by glomeruli from rats
with aortocaval fistula was shown in another study [102] using
an assay system that included 0.5 mM IBMX. Finally, Abraham
et al have observed an appropriate level of cGMP excretion
relative to plasma ANP concentration in patients with heart
failure [103]; this finding disputes the cellular mechanism I
already described for nephrotic ANP resistance. Only further
study will clarify the contributions of these various mecha-
nisms, including altered ANP binding and opposing effects of
antinatriuretic systems as well as cellular changes such as
increased PDE activity, to ANP resistance in these various
physiologic and pathophysiologic responses.
DR. MARTIN G. COGAN (Chief, Division of Nephrology, Ft.
Miley VA Hospital, San Francisco): Have you attempted to
infuse an analogue of cGMP such as dibutyryl-cGMP to see
whether you can overcome the resistance that you described?
DR. HUMPHREYS: That, too, is an important experiment to
carry out. We have not yet had the opportunity to do it, but we
interpret the normalization of both volume-expansion natriure-
sis and UGMpV by zaprinast when infused intrarenally as
suggesting that blunted responsiveness in nephrotic rats is
related to diminished cGMP action.
DR. HARLAN E. Ivus (Chief, Division of Nephrology, Moffitt-
Long Hospital, San Francisco): How would you square the
observation that denervation improves responsiveness to ANP
with the data showing that in-vitro tissues maintain a blunted
response to ANP? Is it possible that the half-life of PDE is long
enough that the defect is still present long after the tissues are
removed?
Da. HUMPHREYS: We have no direct information on that
point. The in-vitro results were obtained on relatively fresh
tissue isolated the same day as the incubation, so the defect
lasts at least a few hours. We are interested in culturing these
IMCD cells to see whether the evidence for increased cGMP
PDE activity is demonstrable after several days. With respect
to the role of the renal nerves, renal denervation failed to
improve volume expansion natriuresis in our study in anesthe-
tized rats [52], but it did restore responsiveness in nephrotic
rats studied in the conscious state [511. Whether other factors
could explain this difference is not currently known.
DR. R. CURTIS Moiuus, JR. (Professor of Medicine, Pediat-
rics, and Radiology, University of California San Francisco):
In that regard, has anyone measured cGMP excretion by
denervated nephrotic kidneys in response to ANP infusion?
DR. HUMPHREYS: Not that I'm aware of. Infusion of ANP
increases UCGMPV by normal kidneys that have been dener-
vated, but I don't believe anyone has examined the response of
denervated nephrotic kidneys.
DR. HENRY HULTER (Division of Nephrology, San Francisco
General Hospital, San Francisco): You mentioned that cQMP
appears to work in the IMCD by an action on the sodium
channel. Are there data on the integrity of the sodium channel
in nephrotic animals? Could there be an abnormality at this
level that accounts for blunted natriuresis?
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DR. HUMPHREYS: I am not aware of any information on
amioride sensitivity of IMCD cells in nephrotic animals, and it
certainly is possible that an abnormality there could contribute
to nephrotic sodium retention. However, the normalization of
the volume expansion response with zaprinast leads me to
conclude that the major abnormality resides in the cGMP
system.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): As you noted,
Kirchner and associates showed that sulfa compounds compete
with furosemide for binding sites in the tubular lumen of
proteinuric rats [91]. Has anyone tried to apply this observation
clinically by using other such drugs? I'm thinking specifically
about whether thiazide diuretics might have some effect.
DR. HUMPHREYS: I believe the only agent that group has
evaluated is furosemide. Although one could try administering
drugs that compete with furosemide for binding to tubular
albumin, I think Brater simply recommends using higher doses
of furosemide to enhance diuretic efficacy in nephrotic patients
[90].
DR. IVES: Many of the PDE inhibitors also have activity
against adenosine receptors. Is it possible that some of the
actions of these agents in the glomerulus and IMCD cell could
be explained by blockade of adenosine receptors at these sites?
DR. HUMPHREYS: I must confess I do not know whether
zaprinast has been tested for effects at adenosine receptors, but
it shares structural similarity with other methylxanthines. As
you know, adenosine's effects on tubular transport are complex
and poorly understood [104], and zaprinast could conceivably
influence adenosine-mediated effects on sodium excretion.
However, I think the in-vitro results would be more difficult to
ascribe to an adenosine receptor effect.
DR. WILLIAM P. MULDOWNEY (Staff Nephrolo gist, Santa
Clara Kaiser Permanente Medical Center, Santa Clara, Cali-
fornia): Patients markedly differ in the degree of edema that
develops as a consequence of the nephrotic syndrome. How do
you reconcile your model with this observation?
DR. HUMPHREYS: That's a good point. I believe that ne-
phrotic patients exist along a continuum: at one end, avid
sodium retention dominates, perhaps through the combination
of underfihl and overflow mechanisms I mentioned earlier, and
edema formation can be disabling. Toward the other end, less
pronounced or absent underfill, and a milder degree of cellular
resistance to ANP, may permit a new steady state to develop
with less severe edema formation. Certainly, nephrotic patients
exhibit a range of sodium avidity, as I pointed out: some excrete
less than 10 mEq of sodium per day, and others demonstrate
positive sodium balance only when challenged with a very high
sodium intake.
Da. DAVID J. MENKE (Staff Nephrologist, San Francisco
Kaiser Permanente Medical Center): In the hypovolemic forms
of nephrosis, you pointed out that some people have postulated
a diffuse leakiness of capillaries because hypoalbuminemia
alone can't explain the low plasma volume. Do you think such
a process could be involved? As you showed, hypoalbuminemia
by itself does not adequately account for the changes leading to
sodium retention.
DR. HUMPHREYS: Although there was initial interest in this
possibility, little attention has been paid to it lately. I believe
this is because researchers have been unable to demonstrate
reduced plasma and blood volumes in the majority of nephrotic
patients, and because, in those patients who are hypovolemic,
a reduced transcapillary oncotic gradient might be the chief
contributor. It does appear, however, that most patients with
functional evidence of hypovolemia have minimal-change ne-
phropathy. This observation leaves open the possibility that a
diffuse capillary leak exists in these patients.
DR. ANTHONY A. PORTALE (Chief, Division of Pediatric
Nephrology, Moffitt-Long Hospital): Along the same lines,
could you comment on the quantitative contribution of in-
creased renal albumin catabolism in the hypoalbuminemia of
nephrotic syndrome?
DR. HUMPHREYS: It is clear that increased albumin catabo-
lism, primarily in the kidneys, must contribute to nephrotic
hypoalbuminemia, because patients with end-stage renal dis-
ease treated with continuous ambulatory peritoneal dialysis
lose amounts of albumin via the dialysate that are comparable
to those excreted in the urine by nephrotic patients, yet they
maintain normal or near-normal serum albumin concentrations
[105]. In individual nephrotic patients, the serum albumin
concentration is determined by the interplay of several factors,
including urinary albumin loss, albumin catabolism, hepatic
albumin synthesis, and albumin distribution between vascular
and extravascular compartments, so it is difficult to offer a
quantitative assessment of one factor without a knowledge of
them all. Today's patient is a good example: on initial presen-
tation, absolute proteinuria was moderate for nephrotic patients
when considered by itself, but when considered in the context
of his low filtered load because of the very low serum albumin
concentration and low GFR, it is massive. Later in his course,
GFR and serum albumin concentration were much higher, yet
protein excretion was about the same.
DR. MARTHA L. GRABER (Division of Nephrology, Mof-
fitt-Long Hospital): Has anyone examined the role of the
renin-angiotensin-aldosterone system in the blunted response to
ANP in the nephrotic animal?
DR. HUMPHREYS: Not specifically. In most experimental
models of nephrosis, it is difficult to document unequivocal
involvement of this system. This finding is in contrast to the
situation in congestive heart failure, another circumstance of
ANP resistance, but one in which activation of the renin-
angiotensin axis is regularly demonstrable, and in which angio-
tensin antagonists and converting enzyme inhibitors improve
ANP resistance [106, 107].
DR. JOSHUA LIPSCHUTZ (Fellow in Nephrology, University of
Cal(fornia San Francisco): What is the effect of converting
enzyme inhibitors on the ANP resistance of heart failure, and
have ACE inhibitors been tried in nephrotic syndrome?
DR. HUMPHREYS: In two separate studies of experimental
heart failure in rats, treatment with an oral converting enzyme
inhibitor restored both the hemodynamic [106] and the renal
[107] actions of ANP infusion, although the basis for this has
not yet been established. With respect to nephrotic syndrome,
I mentioned the study by Brown et al [28], which concluded that
interruption of the renin-angiotensin system by converting
enzyme inhibition did not modify sodium retention in their
nephrotic patients. However, the decrease in blood pressure
caused by the treatment could have blunted a natriuretic effect.
Captopril treatment of rats wit puromycin aminonucleoside
nephrosis also failed to influence sodium retention [1081.
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Da. HARRLNGTON: You hinted that endothelin and other such
compounds could have a role in triggering nephrotic ANP
resistance. What evidence is there indicating an endothelin
abnormality? What are endothelin levels in the various forms of
nephrotic syndrome, and what happens with diuretic treat-
ment?
DR. HUMPHREYS: I am not aware of any information on this
issue.
DR. HULTER: Peterson et a! used a low ANP level as
evidence for an underfilled circulation in nephrotic patients
[32]. Has a low ANP level been a general observation? How
does it correlate with other markers of underfilling such as PRA
and aldosterone concentration?
DR. HUMPHREYS: Unfortunately, resting plasma ANP levels
show no consistent pattern in nephrotic subjects. Many patients
have levels no different than those in normals, and ANP does
not clearly correlate with PRA. Experimental nephrosis in the
rat also seems to lead to no difference in ANP concentration
[52, 60].
DR. COGAN: It has become clear than ANP is a member of a
larger family of natriuretic peptides and, as you alluded, there
also are numerous receptors. Have you had an opportunity to
look at other natriuretic peptides and their possible roles in
nephrotic sodium retention?
DR. HUMPHREYS: As you know, most attention with respect
to the kidney has focused on urodilatin, an ANP family member
differing from ANP by an N-terminal extension of four amino
acids, which is thought to be synthesized exclusively in the
kidney [1091. Urodilatin might be more closely related to the
regulation of sodium excretion than is ANP. We have studied
this compound only to the extent that we have shown that it
exhibits similar binding characteristics to renal receptors and
leads to similar cGMP accumulation as ANP [110]. We also
have documented that glomeruli and IMCD cells isolated from
nephrotic rat kidneys have blunted cGMP accumulation in
response to urodilatin just as they do for ANP [111]. However,
we have not otherwise examined the role of this agent in
experimental nephrosis. Greenwald and colleagues reported
that kidneys of nephrotic rats had increased amounts of ANP-
like compound [112], although how such an increase might
relate to nephrotic sodium retention is not clear.
Da. HULTER: Now that mRNA for ANP has been found in
renal tissue [113], has anyone investigated whether there are
differences in expression in proteinuric states? Do the data you
presented suggest any kind of a local, intrarenal phenomenon in
nephrotic ANP resistance?
DR. HUMPHREYS: No information is yet available on ANP
message levels in nephrosis; as you know, the signal was
vanishingly low and could only be demonstrated by polymerase
chain reaction amplification (113]. I do not yet see how the
model presented of ANP resistance could relate to altered renal
synthesis of urodilatin or other ANP-like compounds, unless
cellular resistance led to a compensatory increase in the syn-
thesis of such a peptide. Although it will be of interest to
examine this possibility, it suggests that the cellular resistance
to ANP develops from some other consequence of the ne-
phrotic state.
DR. IvEs: My comment diverges from the topic of your talk,
but the clinical response of this patient to the therapy he
received is truly remarkable and might obviate the need for any
phosphodiesterase inhibitors in the management of nephrotic
syndrome! Would you care to comment on the treatment, a
rather short course of treatment at that?
DR. HUMPHREYS: I share with you a sense of amazement that
he could recover so much renal function and clear the severe
edema he had on initial presentation with the interrupted
protocol he received. As I said at the outset, this is a subject
worthy of its own Nephrology Forum, which Dr. Ponticelli
already has given [1]. Perhaps he should be invited back for a
return visit!
Reprint requests to Dr. M. Humphreys, Division of Nephrology, San
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